Metastatic breast cancer treatment with DC-CIK immunotherapy

This is a treatment result comparison between two groups of breast cancer patients.

Patients in control group receive chemotherapy only. Patients in comparison group receive chemotherapy and immunotherapy.

Significant rising of lymphocyte (CD3+), helper T cells (CD3+/CD4+), NK cells (CD3-/CD16+56+) and NKT cells was observed 7 days after the treatment with DC-CIK immunotherapy. In contrast, suppressor T cells decreased. These indicated remarkable improvement on immune response of patients in comparison group.

None of these was observed in the test result from patients in the control group.

Breast Cancer

 

Share this article

Effective and affordable immunotherapy and CAR T-cell Therapy?

Contact us and get detailed information about getting advanced immunotherapy and CAR T-cell therapy for the treatment of solid tumors, blood cancers and HPV infection.